Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br In conclusion we have developed a simple

    2022-09-08


    In conclusion, we have developed a simple, pragmatic, prognostic model using performance status, distant metastases and weight loss im-mediately prior to diagnosis predict for overall survival in older patients with advanced non-small cell lung cancer.
    Funding Source
    Conflicts of Interest
    None of the authors has any conflicts of interest with the contents of this MCC950 manuscript .
    Author Contributions
    Study concepts: Apar Kishor Ganti, Xiaofei Wang, Herbert Pang
    Study design: Apar Kishor Ganti, Xiaofei Wang, Thomas E. Stinchcombe, Herbert Pang
    Data acquisition: Apar Kishor Ganti, Xiaofei Wang, Thomas
    E. Stinchcombe, Jeffrey Bradley Harvey J. Cohen, Karen Kelly, Rebecca
    Paulus, Suresh S. Ramalingam, Everett E. Vokes, Herbert Pang
    Quality control of data and algorithms: Xiaofei Wang, Herbert Pang,
    Yinpeng Wang
    Data analysis and interpretation: Apar Kishor Ganti, Xiaofei Wang, Thomas E. Stinchcombe, Herbert Pang, Yinpeng Wang Statistical analysis: Xiaofei Wang, Herbert Pang, Yinpeng Wang
    Manuscript preparation: Apar Kishor Ganti, Xiaofei Wang, Thomas
    E. Stinchcombe, Herbert Pang
    Manuscript editing: All Authors
    Manuscript review: All Authors
    Appendix A. Supplementary Data
    Supplementary data to this article can be found online at https://doi.
    References
    [3] Socinski M, Creelan B, Horn L, Reck M, Paz-Ares L, Steins M, et al. NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC. Ann Oncol 2016;27(suppl_6) LBA7_PR-LBA_PR.
    [6] Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19(4):1064–70. [7] Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117 (5):1239–46.
    [9] Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010;28(4):620–7.
    [10] Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. J Clin Oncol 2008; 26(1):60–5.
    [11] Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, et al. A prognostic model for advanced stage nonsmall cell lung cancer: pooled anal-ysis of north central cancer treatment group trials. Cancer 2006;107(4): 781–92.
    [12] Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, et al. 4-year mor-tality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 2006;7(10):829–36.
    [16] Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung can-cer: a decade of progress. Chest 2002;122(3):1037–57. [17] Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, International Staging C, et al. The impact of additional prognostic factors on survival and their re-lationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for MCC950 the 7th edition. J Thorac Oncol 2008;3(5):457–66.
    [18] Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are G banding independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5(5):620–30.